MT1JP and hepatocellular carcinoma: The Lenvatinib sensitive group exhibited a lower expression of MT1JP and a higher expression of miR-24-3p compared to the Lenvatinib insensitive group (Fig. 6b), which is in accordance with the in vitro HCC cell line data.